Effects of Kanglaite injection combined with gefitinib on inflammatory factors and immune function with advanced lung cancer
10.3969/j.issn.1005-1678.2016.12.042
- VernacularTitle:康莱特注射液联合吉非替尼对晚期肺癌患者炎性因子与免疫功能的影响
- Author:
Jianjiang JIN
;
Qilei HU
;
Tao QIU
- Keywords:
gefitinib;
Kanglaite injection;
combine;
advanced lung cancer;
inflammatory factor;
immune function
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(12):147-150
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study effects of Kanglaite injection combined with gefitinib on inflammatory factors and immune function in patients with advanced lung cancer.Methods 98 patients with advanced lung cancer in First People 's Hospital of Yuhang District from December 2013 to September 2016 were selected and randomly divided into gefitinib-treated group and combination drug-treated group with 49 cases in each group.The patients in the gefitinib-treated group were treated with gefitinib, the patients in the combination drug-treated group were treated with gefitinib and Kanglaite injection.The clinical efficacy, inflammatory factors, immune function, quality of life and adverse reactions were observed and compared between the two groups. Results The efficacy and control rate in combination drug-treated group were higher than gefitinib-treated group(P<0.05).The inflammatory factors such as CRP, IL-6 and TNF-αwere significantly improved in the two groups before treatment, and the combination drug-treated group improved significantly better than gefitinib-treated group(P<0.05).The levels of cellular immune factors in the two groups were significantly improved compared with that before treatment, and the combination drug-treated group was significantly better than the gefitinib-treated group(P<0.05).The quality of life in the combination drug-treated group was significantly higher than the gefitinib-treated group(P<0.05).The incidence of adverse reactions such as nausea and vomiting, thrombocytopenia, and renal dysfunction in combination drug-treated group was lower than in the gefitinib-treated group( P<0.05).Conclusion Application of gefitinib combined with Kanglaite injection in the treatment of patients with advanced lung cancer treatment is more significant, can effectively reduce the systemic inflammation and adverse reactions, improve immune function and quality of life.
